Pulmonx Corporation (NASDAQ:LUNG) Q2 2024 Earnings Conference Call July 31, 2024 4:30 PM ET Company Participants Elizabeth Sparicio - Investor Relations Steve Williamson - President & Chief Executive Officer Mehul Joshi - Chief Financial Officer Conference Call Participants Jason Bednar - Piper Sandler John Young - Canaccord Frank Takkinen - Lake Street Capital Markets Operator Ladies and gentlemen, thank you for standing by. Welcome to the Pulmonx Second Quarter 2024 Earnings Conference Call. At this time ...

Pulmonx Corporation (LUNG) came out with a quarterly loss of $0.39 per share versus the Zacks Consensus Estimate of a loss of $0.41. This compares to loss of $0.43 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 4.88%. A quarter ago, it was expected that this company would post a loss of $0.43 per share when it actually produced a loss of $0.36, delivering a surprise of 16.28%. Over the last four quarters, the company has sur ...

REDWOOD CITY, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) ("Pulmonx" or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the second quarter of 2024 ended June 30, 2024. Recent Highlights Achieved record worldwide revenue of $20.8 million in the second quarter of 2024, a 21% increase over the same period last year and an increase of 21% on a constant currency basis Delivered $13.9 million in U.S. revenue i ...

Company Overview - Pulmonx Corporation is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD) [2] - The company's key products include the Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System, and StratX® Lung Analysis Platform, which are designed to assess and treat severe emphysema/COPD patients [2] - The Zephyr Valve has received FDA pre-market approval and is commercially available in over 25 countries, recognized as a standard of care treatment option for severe emphysema [2] Product and Market - The Zephyr Valve is designated as a "breakthrough device" by the FDA, highlighting its innovative nature and potential impact on patient care [2] - The Zephyr Valve is included in global treatment guidelines, indicating its widespread acceptance and adoption in the medical community [2] Investor Relations - Pulmonx Corporation will present at the Canaccord Genuity 44th Annual Growth Conference in Boston on August 13, 2024, at 5:00 AM PT / 8:00 AM ET [4] - A live and archived webcast of the presentation will be available on the "Investors" section of the Pulmonx website [1]

Timeline and Key Milestones As I look at the strategy that's in place, I think it's the right strategy. I think we've shown growth or the company has shown growth over prior quarters and it's been effective. I think over time, we'll probably make some small refinements or add some specificity to different arms of it over time. But I think all in all, our ability to bring on accounts that can be big Zephyr Valve users or big Zephyr Valve treatment centers is important. We'll continue to do that. On the posit ...

Contact Brian Johnston Gilmartin Group investors@pulmonx.com REDWOOD CITY, Calif., July 10, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) ("Pulmonx"), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the second quarter of 2024 after the close of trading on Wednesday, July 31, 2024. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET. A live and archived ...

Shares of Pulmonx Corporation (LUNG) have gained 17.1% over the past four weeks to close the last trading session at $8.78, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $15.83 indicates a potential upside of 80.3%. The mean estimate comprises six short-term price targets with a standard deviation of $1.72. While the lowest estimate of $14 indicates a 59.5% increase from the c ...

Breakthrough DLL3-Targeting Therapy Regimen for a Major Solid Tumor IMDELLTRA Demonstrated Impressive 40% Objective Response Rate, 9.7 Month Median Duration of Response and 14.3 Month Median Overall Survival in Pivotal DeLLphi-301 Study Amgen to Host Webcast Investor Call on May 20, 2024 at 1:00 p.m. PT THOUSAND OAKS, Calif., May 16, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved IMDELLTRA™ (tarlatamab-dlle) for the treatment of adult p ...

REDWOOD CITY, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) ("Pulmonx" or the "Company"), a global leader in minimally invasive treatments for lung disease, today announced that the Compensation Committee of the Board of Directors of Pulmonx (the "Compensation Committee") granted inducement awards consisting of a non-statutory stock option to purchase 241,409 shares of common stock and a time-based restricted stock unit award for 125,870 shares of common stock on May 6, 2024 to ...

Shares of Pulmonx Corporation (LUNG) have gained 19.2% over the past four weeks to close the last trading session at $9.82, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $15.33 indicates a potential upside of 56.1%.The average comprises six short-term price targets ranging from a low of $12 to a high of $18, with a standard deviation of $2.34. While the lowest estimate indicat ...